search icon
Join IDSAJOIN IDSA >> Go to MyIDSAGO TO MYIDSA >>
  • Print
  • ShareThis
  • Text Size

IDSA Practice Guidelines

Practice guidelines are systematically developed statements to assist practitioners and patients in making decisions about appropriate health care for specific clinical circumstances. [Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines, 1990]

Attributes of good guidelines include validity, reliability, reproducibility, clinical applicability, clinical flexibility, clarity, multidisciplinary process, review of evidence, and documentation. [Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines, 1990]

Keyword Search

...

Search Results

51 results found

Cysticercosis

Status: Current

Guidelines for the clinical management of patients with neurocysticercosis (NCC) were prepared by a panel of the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine

Guidelines for the clinical management of patients with neurocysticercosis (NCC) were prepared by a panel of the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). The guidelines are intended for infectious disease specialists, neurologists, neurological surgeons, internists, pediatricians, and family practitioners.These guidelines present our approaches to the diagnosis and management of patients with the different forms of neurocysticercosis, including viable parenchymal neurocysticercosis, single enhancing lesions, calcified parenchymal neurocysticercosis, ventricular neurocysticercosis, and subarachnoid neurocysticercosis. Our recommendations are based on the best evidence available. Due to the complex variations in clinical manifestations and the limitations of the literature, many of the recommendations are based on observational studies, anecdotal data, or expert opinion rather than randomized clinical trials. The approaches we describe are intended to be both applicable and feasible in the United States and Canada (for simplicity, referred to here as North America). The recommendations may not apply for settings where resource constraints may limit their applicability.Full text*Every 12 to 18 months following publication, IDSA reviews its guidelines to determine whether an update is required. The guideline was published February of 2018 and is the most current version.

Fever and Neutropenia in Adults with Cancer

Status: Current

This updated joint ASCO/Infectious Diseases Society of American (IDSA) guideline provides direction on outpatient management of fever and neutropenia in patients with cancer.Full text

This updated joint ASCO/Infectious Diseases Society of American (IDSA) guideline provides direction on outpatient management of fever and neutropenia in patients with cancer.Full text

Clostridium difficile

Status: Current

A panel of experts was convened by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) to update the 2010 clinical practice guideline on

A panel of experts was convened by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) to update the 2010 clinical practice guideline on Clostridium difficile infection (CDI) in adults. The update, which has incorporated recommendations for children (following the adult recommendations for epidemiology, diagnosis, and treatment), includes significant changes in the management of this infection and reflects the evolving controversy over best methods for diagnosis. Clostridium difficile remains the most important cause of healthcare-associated diarrhea and has become the most commonly identified cause of healthcare-associated infection in adults in the United States. Moreover, C. difficile has established itself as an important community pathogen. Although the prevalence of the epidemic and virulent ribotype 027 strain has declined markedly along with overall CDI rates in parts of Europe, it remains one of the most commonly identified strains in the United States where it causes a sizable minority of CDIs, especially healthcare-associated CDIs. This guideline updates recommendations regarding epidemiology, diagnosis, treatment, infection prevention, and environmental management.Full text*Every 12 to 18 months following publication, IDSA reviews its guidelines to determine whether an update is required. The guideline was published February of 2018 and is the most current version.

SHEA/CDC Outbreak Response Training Program Expert Guidance

Status: Current, Endorsed

This expert guidance document was developed as a resource to provide healthcare epidemiologists working in acute-care hospitals with a high-level overview of incident management for infectious diseases outbreaks and to

This expert guidance document was developed as a resource to provide healthcare epidemiologists working in acute-care hospitals with a high-level overview of incident management for infectious diseases outbreaks and to prepare them to work within an emergency response framework. It addresses how the epidemiologist’s skills and expertise apply to scenarios that require enhanced preparedness and response efforts, eg, when pathogens associated with outbreaks are poorly characterized or when outbreaks require additional interventions including, but not limited to, healthcare personnel education, enhanced infection prevention and control measures, added staffing, supplies, and resources, adjustments to clinical and support activities, and external communications. Its recommendations are not pathogen-specific and are meant to apply to a range of potential infectious diseases outbreaks. To provide high-level guidance and context for incident management, the authors specify recommendations for the healthcare epidemiologist, as well as involvement and responsibilities of the facility and other healthcare personnel (HCP).Full Text

Diarrhea

Status: Current

*Every 12 to 18 months following publication, IDSA reviews its guidelines to determine whether an update is required. This guideline was published in October 2017 and is the most current

*Every 12 to 18 months following publication, IDSA reviews its guidelines to determine whether an update is required. This guideline was published in October 2017 and is the most current version.The widening array of recognized enteric pathogens and the increasing demand for cost-containment sharpen the need for careful clinical and public health guidelines based on the best evidence currently available. Adequate fluid and electrolyte replacement and maintenance are key to managing diarrheal illnesses. Thorough clinical and epidemiological evaluation must define the severity and type of illness (e.g., febrile, hemorrhagic, nosocomial, persistent, or inflammatory), exposures (e.g., travel, ingestion of raw or undercooked meat, seafood, or milk products, contacts who are ill, day care or institutional exposure, recent antibiotic use), and whether the patient is immunocompromised, in order to direct the performance of selective diagnostic cultures, toxin testing, parasite studies, and the administration of antimicrobial therapy (the latter as for traveler's diarrhea, shigellosis, and possibly Campylobacter jejuni enteritis). Increasing numbers of isolates resistant to antimicrobial agents and the risk of worsened illness (such as hemolytic uremic syndrome with Shiga toxin-producing Escherichia coli O157:H7) further complicate antimicrobial and antimotility drug use. Thus, prevention by avoidance of undercooked meat or seafood, avoidance of unpasteurized milk or soft cheese, and selected use of available typhoid vaccines for travelers to areas where typhoid is endemic are key to the control of infectious diarrhea.Full text

HCV Guidance

Status: Current

New direct-acting oral agents capable of curing hepatitis C virus (HCV) infection have been approved for use in the United States. The initial direct-acting agents were approved in 2011, and

New direct-acting oral agents capable of curing hepatitis C virus (HCV) infection have been approved for use in the United States. The initial direct-acting agents were approved in 2011, and many more oral drugs are expected to be approved in the next few years. As new information is presented at scientific conferences and published in peer-reviewed journals, health care practitioners have expressed a need for a credible source of unbiased guidance on how best to treat their patients with HCV infection. Full text

HIV Chronic Pain Management

Status: Current

Pain has always been an important part of human immunodeficiency virus (HIV) disease and its experience for patients. In this guideline, we review the types of chronic pain commonly seen

Pain has always been an important part of human immunodeficiency virus (HIV) disease and its experience for patients. In this guideline, we review the types of chronic pain commonly seen among persons living with HIV (PLWH) and review the limited evidence base for treatment of chronic noncancer pain in this population. We also review the management of chronic pain in special populations of PLWH, including persons with substance use and mental health disorders. Finally, a general review of possible pharmacokinetic interactions is included to assist the HIV clinician in the treatment of chronic pain in this population.Full Text*Every 12 to 18 months following publication, IDSA reviews its guidelines to determine whether an update is required. The guideline was published September of 2017 and is the most current version.

HRS: Cardiovascular Implantable Electronic Device Lead Management and Extraction

Status: Current, Endorsed

The 2017 HRS Expert Consensus Statement on Cardiovascular Implantable Electronic Device Lead Management and Extraction, developed in collaboration with the ACC, AHA, APHRS, ASA, EHRA, IDSA, LAHRS, PACES, and STS,

The 2017 HRS Expert Consensus Statement on Cardiovascular Implantable Electronic Device Lead Management and Extraction, developed in collaboration with the ACC, AHA, APHRS, ASA, EHRA, IDSA, LAHRS, PACES, and STS, is intended to help clinicians in their decision-making process for managing leads and builds on the 2009 Transvenous Lead Extraction: Heart Rhythm Society Expert Consensus on Facilities, Training, Indications, and Patient Management document. It provides practical clinical guidance in the broad field of lead management, including lead extraction.The statement focuses on identifying the presence of lead malfunction, deciding on whether to abandon or to extract a lead that is no longer clinically necessary or at higher risk for failure, offering guidance on whether a cardiovascular implantable electronic device (CIED) is involved in an infectious process, providing recommendations on when lead extraction should be considered, and discussing specific clinical considerations for patient management when a lead extraction is performed.The document includes specific recommendations in the following areas: Lead SurvivalExisting CIED Lead ManagementIndications for Lead Extraction (Infectious)Indications for Lead Extraction (Noninfectious)Outcomes and Follow-up  Full Text

Prevention and Treatment of Opportunistic Infections Among Adults and Adolescents

Status: Current

Updated guidelines for the prevention and treatment of opportunistic infections in HIV-Infected adults and adolescents.*Last updated March 28, 2017.*For information on the timing of future updates to this guideline, contact AIDSinfo.

Updated guidelines for the prevention and treatment of opportunistic infections in HIV-Infected adults and adolescents.*Last updated March 28, 2017.*For information on the timing of future updates to this guideline, contact AIDSinfo.

Healthcare-Associated Ventriculitis and Meningitis

Status: Current

The Infectious Diseases Society of America (IDSA) Standards and Practice Guidelines Committee collaborated with partner organizations to convene a panel of 10 experts on healthcare-associated ventriculitis and meningitis. The panel

The Infectious Diseases Society of America (IDSA) Standards and Practice Guidelines Committee collaborated with partner organizations to convene a panel of 10 experts on healthcare-associated ventriculitis and meningitis. The panel represented pediatric and adult specialists in the field of infectious diseases and represented other organizations whose members care for patients with healthcare-associated ventriculitis and meningitis (American Academy of Neurology, American Association of Neurological Surgeons, and Neurocritical Care Society). The panel reviewed articles based on literature reviews, review articles and book chapters, evaluated the evidence and drafted recommendations. Questions were reviewed and approved by panel members. Subcategories were included for some questions based on specific populations of patients who may develop healthcare-associated ventriculitis and meningitis after the following procedures or situations: cerebrospinal fluid shunts, cerebrospinal fluid drains, implantation of intrathecal infusion pumps, implantation of deep brain stimulation hardware, and general neurosurgery and head trauma. Recommendations were followed by the strength of the recommendation and the quality of the evidence supporting the recommendation. Many recommendations, however, were based on expert opinion because rigorous clinical data are not available. These guidelines represent a practical and useful approach to assist practicing clinicians in the management of these challenging infections. Full text*Every 12 to 18 months following publication, IDSA reviews its guidelines to determine whether an update is required. The guideline was published February of 2017 and is the most current version.

| HIVMA | Contact Us

© Copyright IDSA 2018 Infectious Diseases Society of America

Full Site Mobile Site